Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
about
Cardiovascular safety of phosphodiesterase inhibitors for treating erectile dysfunction in elderly menThe role of statins in erectile dysfunction: a systematic review and meta-analysisThe pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertensionSexual function in hypertensive patients receiving treatmentStimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissueRole of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts.Recognition and management of complications during moderate and deep sedation. Part 2: cardiovascular considerationsErectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.African traditional medicines for erectile dysfunction: elusive dream or imminent reality?Optic neuropathy associated with the use of over-the-counter sexual enhancement supplements.Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training.Sexual counseling and cardiovascular disease: practical approaches.Management of erectile dysfunction post-radical prostatectomyManagement of complications during moderate and deep sedation: respiratory and cardiovascular considerations.Erectile dysfunction and hypertension: impact on cardiovascular risk and treatmentSildenafil in the treatment of pulmonary hypertension.Erectile dysfunction in patients with coronary artery disease.An Observational Study to Evaluate the Prevalence of Erectile Dysfunction (ED) and Prescribing Pattern of Drugs in Patients with ED Visiting an Andrology Specialty Clinic, Mumbai: 2012-14.Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem.A multidisciplinary approach to assess erectile dysfunction in high-risk cardiovascular patients.Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction.The use of phosphodiesterase 5 inhibitors with concomitant medications.Phosphodiesterase 5 inhibitors: are they cardioprotective?How to save a life during a clinic visit for erectile dysfunction by modifying cardiovascular risk factors.Comparative efficacy of tamsulosin versus tamsulosin with tadalafil in combination with prednisolone for the medical expulsive therapy of lower ureteric stones: a randomized trialDrug-related problems in patients with erectile dysfunctions and multiple comorbidities.Erectile dysfunction as a complication of heart failure.Vardenafil orodispersible tablet.Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics.Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.Sexual activity and ischemic heart disease.Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance.Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitusIs the use of plants in Jordanian folk medicine for the treatment of male sexual dysfunction scientifically based? Review of in vitro and in vivo human and animal studies.The risk of cardiovascular side effects with anti-anginal drugs.Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.Drug Therapy for Stable Angina Pectoris.Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.
P2860
Q24194249-CB291908-8DAC-4DC9-BD2F-30B1A9FD8A14Q26823131-49EDEA67-5416-43AA-8168-48D6FB70C92EQ26852171-1ED50764-8A7B-4B26-A1BD-FCF534845EF3Q28219420-270B6749-BBE2-4DEE-A711-EE82A10DD3C5Q30316523-44E95205-7C31-4510-AD0F-EB9F8D56DEF0Q30575578-918B2E5A-BCC0-4696-9791-1AC2D5CFF363Q33160401-62DD55F3-43C9-491C-B449-7D63F54C7796Q33710298-F75A854F-7DEA-4BA9-BA2B-8426AE7BFE8AQ34220033-C542C574-5B18-47D3-A8C0-943BF4FBA0F0Q34446356-8F0064C9-D4AE-43C4-9A2A-E16101C16EF6Q34905015-5D8F0B91-546D-4387-99C3-33018316BDB7Q34927898-CD798ABA-6048-4D86-B475-2921BEFD27BBQ35142432-3B03DD40-ADB4-4F23-BDF0-7FF81AE3BE4CQ35845016-6479B220-5AB8-474C-B0CF-CE5E13508E6FQ35977540-A2BC4033-51F3-49F7-867B-7958AD4ADE81Q36013070-B4480C03-1B04-4BAC-831B-D17E49317F97Q36053660-F92B46D8-CAB9-4395-91F0-D736EBF22BAAQ36068178-D3B24D2F-689E-455A-B2AA-CE7CCC06807EQ36150572-0694BCCA-5079-4FB8-9BD6-E394F206FFA4Q36359845-9648B242-377C-48C6-ADEF-EFD6FCAEEE69Q36359849-FEDA59AB-093A-49B6-9B76-DC406C8A0EADQ36689825-D6F306CF-6A45-4CCF-B4F1-D65277B83606Q36808042-156E771E-0894-4AB3-9EA4-7E28FB35CC49Q37321940-364CE340-0B9C-4026-8E34-A3F170AAB502Q37497840-74C0C3CC-6F2F-4CDE-9A1B-7A4D6CAB14AFQ37582767-C507ED73-20AD-4269-BFD2-2B509C4CB286Q37642106-EB1F6157-D415-42A9-8931-4E49E586AC5DQ37742049-F41000F0-5FCA-44C5-97CB-BCBECC1BA29BQ37776171-B2B3DA91-B299-44DE-9F99-4F1B735A7947Q37970759-84453E42-E297-4170-A0CA-9010A38C59B4Q38004987-C48A9117-1A14-4F65-B064-3089526E36CAQ38126803-B83511D4-A319-469D-A491-76644A371433Q38177225-21380BD5-D91C-4620-8D1F-0B6BDD687F36Q38199072-312487A9-AADC-4A34-9709-2F331AE763C8Q38466768-EBB5434F-DE10-4756-8753-96FE7A7C6F91Q38867698-E8AC4AD4-92AE-4183-8D6D-13C41C3FC475Q38962046-442B8499-370E-484E-A86F-E66B2B990F5AQ39020015-0DD9B13A-24C8-4647-BC1E-D7CA5699E4EFQ39102158-E5D4AEE6-07D6-467C-9F52-F64A79D15159Q39141728-A13E3ACC-FB80-4C9F-9B92-4675C0901B2E
P2860
Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cardiovascular effects of the ...... tment of erectile dysfunction.
@ast
Cardiovascular effects of the ...... tment of erectile dysfunction.
@en
type
label
Cardiovascular effects of the ...... tment of erectile dysfunction.
@ast
Cardiovascular effects of the ...... tment of erectile dysfunction.
@en
prefLabel
Cardiovascular effects of the ...... tment of erectile dysfunction.
@ast
Cardiovascular effects of the ...... tment of erectile dysfunction.
@en
P1433
P1476
Cardiovascular effects of the ...... tment of erectile dysfunction.
@en
P2093
Robert A Kloner
P304
P356
10.1161/01.CIR.0000146906.42375.D3
P407
P577
2004-11-01T00:00:00Z